Acadia Pharma GAAP EPS of $0.20 beats by $0.03, revenue of $241.96M beats by $6.3M

Acadia Pharma press release (NASDAQ:ACAD): Q2 GAAP EPS of $0.20 beats by $0.03.
Revenue of $241.96M (+46.4% Y/Y) beats by $6.3M.
At June 30, 2024, Acadia’s cash, cash equivalents, and investment securities totaled $500.9 million, compared to $438.9 million at December 31, 2023.
Updated 2024 Outlook: NUPLAZID net product sales guidance has increased to a range of $590 to $610 million from the previous range of $560 to $590 million, reflecting stronger underlying demand driving recent higher unit volume.
DAYBUE’s net product sales guidance has decreased to a range of $340 to $370 million from the previous range of $370 to $420 million.
Total revenue guidance is revised to a range of $930 to $980 million vs. consensus of $954.19M from the previous range of $930 million to $1.01 billion.
R&D expense guidance is narrowed to the lower end of the previous range and is now expected to be between $305 to $315 million.
SG&A expense guidance is narrowed to the higher end of the previous range and is now expected to be between $465 to $480 million
Shares -15.12%.

Tags: ACAD